Member Info for Laura2022

BOTAK

Do you think COIN could be 10-20p soon please?

Daned

Morning

Where do you see COIN heading ?

SWC is £80mln market cap for eg

Bitcoin Magazine

@BitcoinMagazine

JUST IN: UK public company Coinsilium Group raises £1.25 million to adopt a #Bitcoin treasury strategy

Ot ask Davey why he went quiet on ROQ TLY

COIN going to be next 10 bagger like SWC, CTAI

Malcolm Palle, Executive Chairman of Coinsilium, commented:

“I am delighted to announce this Placing today. We have been very pleased by the response to the Company’s Forza! Initiative and these funds will allow us to advance the implementation of our Bitcoin Treasury Strategy.

Notes to Editors

About Coinsilium

Coinsilium is an investor, advisor and venture builder at the forefront of Web3 convergence. The Company invests in and accelerates Web3 and AI-powered technology start-ups whilst supporting their development and commercialisation.

 

Coinsilium also provides strategic advisory services to start-ups looking to issue tokens through token generation events. Coinsilium’s wholly owned subsidiary, Coinsilium (Gibraltar) Limited, serves as the Company’s operational hub in Gibraltar.

Will do x 10 bags like SWC

Backers here apparently have 40,000 followed in bitcoin space

Maybe ?

Potential value of the PYCDosing tool (s)

From a poster KingHomerJ

The Dosing tool currently in Trial with the NHS Blackpool & Dosemerx is huge for PYC - This trial is due to end in October...

Company Maker......

Estimated Market Size & Tool Value Potential

1. Addressable Market:

o The global precision oncology market is projected to exceed £80 billion by 2030.

o GCSF-related neutropenia management alone represents a multi-billion-dollar submarket within oncology care.

o If Physiomics targets just 1% of high-risk chemotherapy patients in the UK, EU, and US (~1 million annually), and charges:

 £100–£500 per dosing license per patient, the potential annual revenue could be:

 £100M to £500M with adoption.

2. Conservative Valuation Estimate - Based on early-stage rollout and realistic adoption curves:

o Short-term: £500K–£2M revenue potential

o Mid-term £5M–£20M if integrated into mainstream platforms like DoseMeRx, adopted by NHS trusts, or licensed globally

o Exit/Acquisition Scenario: If successful, the tool and IP could attract acquisition interest at multi revenue multiples, yielding a £250M–£500M+ valuation

Value Drivers

• Clinical validation (PREDICT-ONC trial success)

• Integration with EHR and dosing platforms

• Regulatory approvals (NICE, FDA pathways)

• Licensing or subscription model scalability

• Partnership leverage (e.g., with Beyond Blood, DoseMe)

Jupiter, FL – May 15, 2025

DoseMe, a leading provider of Bayesian model-informed precision dosing (MIPD), today announced the launch of a new analytics user interface, designed to deliver a more intuitive experience and lay the foundation for continuous innovation in data analytics.

This update is more than just a visual upgrade. It introduces a modernized infrastructure that enhances performance, improves clarity, and prepares the Analytics suite for rapid feature development, ultimately enabling clinicians to gain faster, clearer, and more actionable insights.

“We’re committed to helping clinical teams make confident, data-driven decisions and have regular exciting additions and updates to the analytics package based on continued customer feedback,” said Sharmeen Roy, PharmD, BCPS, chief science and strategy officer at DoseMe. “This analytics refresh is a major step forward in our journey to provide the tools clinicians need to optimize care and drive precision.”

6th March 2025

Following this, the objective is to commercially launch the software tool by adding paid functionality. To date, implementation of the dosing software onto the DoseMeRx platform is undergoing its final sprint, with minor bugs being addressed following several internal evaluation cycles. The Company is exploring a deeper relationship with DoseMe to develop additional models to be implemented on their platform.

Fantastic news

Is this the "final sprint " final phase of the PYC/DoseMeRx full launch

He was a complete nutter

Nothing he said made sense

I filtered him 5 weeks ago

Was he genuinely that strange or just an act ?

Scdm

According to telegram another offer for AGFX coming next week or so

Watching for 1st entry

Dividend

Victorian Plumbing has a robust balance sheet, generates significant operating cashflows and the underlying priority is to reinvest into the business and drive further profitable growth. Recognising that most growth opportunities do not require significant capital and reflecting confidence in the Group's ongoing strength, future growth prospects and cash generation, Victorian Plumbing has updated its capital allocation policy with the aim of maintaining a dividend cover ratio of 2.25x - 3.00x (previously 3.00x - 3.50x). The policy includes the consideration that the Board may from time to time conclude that it has surplus cash, at which point it will consider further returns to shareholders.

The Board has declared an interim dividend of 0.70 pence per share (H1 2024: 0.52 pence per share), which represents a total cash distribution to shareholders of £2.3m (H1 2024: £1.7m). The dividend will be paid on 15 August 2025 to shareholders on the register of members at the close of business on 18 July 2025.

This is just too funny

VAST will 100% do a discounted raise

TommyD25

Posted in: VAST

Posts: 117

Price: 0.435

No Opinion

Re read the last RNS about diamonds!!!!! Its massiveToday 12:54

Fully funded

New Nomad, director and now office

PLUS

"The total quantity of diamonds included in the Historic Parcel is now estimated to be 135,139.47 carats, of which an aggregate 36,475.26 carats have already been identified to be gem quality"

The 36.5k gem quality... is worth 3 times this mcap alone

Do some research BUT this is absolutely going to hit 1p on the sell announcement... it could do 2p eventually

Thanks

Surely they wouldn't/don't need to place just 5mths after last one

?

From.prelims

The Group enters the remainder of 2025 with replenished but limited cash resources. The Directors have concluded, as was the case at the previous year end, that material uncertainties exist which may cast significant doubt on the Group and Company's ability to continue as a going concern. Stakeholders' attention is drawn to the more detailed commentary on the Directors' assessment of the reasonableness of continuing to adopt the going concern assumption in the preparation of the accounts in Note 2.

 

Even after placing and with £1mln per month cash burn/loss there ws a material concern in last results

Anyone think it's that?